PMC:6650341 / 30093-30807 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6650341","sourcedb":"PMC","sourceid":"6650341","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6650341","text":"4. Conclusion\nSeveral genetic polymorphisms that affect pro-oxidant and antioxidant systems, directly or indirectly, are associated with hypertension. Antioxidants can reduce the blood pressure in humans and animal models of hypertension. Antihypertensive drugs can also have anti-oxidant effects. However, an indiscriminate decrease in ROS production can have deleterious consequences. ROS are involved in the regulation of essential cellular processes. Thus, the long-term administration of drugs with antioxidant properties may impair vital cellular function, resulting in undesirable side effects. Studies are needed to elucidate the role of pharmacogenomics in redox balance in the treatment of hypertension.","divisions":[{"label":"label","span":{"begin":0,"end":2}},{"label":"title","span":{"begin":4,"end":14}}],"tracks":[]}